Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]

DRUG6 trials

Conditions

Chronic Rhinosinusitis With Nasal PolypsChronic Rhinosinusitis Without Nasal PolypsEosinophilic Esophagitis (EoE)Olfactory DisorderSevere Eosinophilic Chronic Sinusitis Without Nasal Polyposis

Early Phase 1

Comparison of Eohilia With Dupixent on Esophagus Diameter in Patients With Eosinophilic Esophagitis.

Enrolling by invitationNCT07358234

Mayo ClinicEosinophilic Esophagitis (EoE)

Start: 2026-02-04End: 2027-12-01Target: 60Updated: 2026-05-04

Phase 2

Dupilumab Severe Eosinophilic Chronic Sinusitis Without Nasal Polyposis

Active, not recruitingNCT04430179

University of South FloridaSevere Eosinophilic Chronic Sinusitis Without Nasal Polyposis

Start: 2020-12-17End: 2025-07-31Target: 30Updated: 2025-01-24

Phase 4

Olfactory Outcomes of Dupilumab Treatment for Nasal Polyposis

RecruitingNCT04869436

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sChronic Rhinosinusitis With Nasal Polyps, Olfactory Disorder

Start: 2021-07-19End: 2025-12-01Target: 27Updated: 2024-12-20

Effect of Dupilumab on the Muscle Function of the Esophagus (food Pipe) in Participants with Eosinophilic Esophagitis (EoE)

RecruitingNCT06665971

University of California, San DiegoEosinophilic Esophagitis (EoE)

Start: 2024-11-10End: 2026-11-14Target: 30Updated: 2024-12-11

Unknown Phase

Dupilumab in the Treatment of Severe Uncontrolled CRSwNP: a Multicentre Observational Real-life Study (DUPIREAL)

NCT05529784

Fondazione Policlinico Universitario Agostino Gemelli IRCCSChronic Rhinosinusitis With Nasal Polyps

Start: 2021-10-06End: 2023-10-01Target: 600Updated: 2023-02-21

Effect of Dupilumab on Nasal Epithelial Barrier Function in Patients With CRSwNP

RecruitingNCT06398873

Medical University of ViennaChronic Rhinosinusitis With Nasal Polyps, Chronic Rhinosinusitis Without Nasal Polyps